王滨

Cooley advised Shoreline Biosciences, Inc., a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, in its strategic partnership with Kite, a Gilead Company (Nasdaq: GILD) to develop novel cell therapies across a variety of cancer targets. Under the terms of the agreement, Shoreline will receive an upfront payment and will be eligible to receive additional payments totaling over $2.3 billion as well as royalties based on achievement of certain development and commercial milestones.

Read more

Cooley advised Shoreline Biosciences, Inc., a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases,  in its  exclusive worldwide strategic collaboration with BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a global biotechnology company, to develop and commercialize a portfolio of NK-based cell therapeutics with Shoreline’s iPSC NK cell technology and BeiGene’s research and clinical development capabilities for different malignancies. Under the terms of the agreement, Shoreline will receive an upfront cash payment of $45 million from BeiGene and will be eligible to receive additional R&D funding, milestone payments and royalties based upon the achievement of certain development, regulatory, and commercial milestones.  In connection with the agreement, BeiGene has an option to acquire an equity stake in Shoreline in its next round of equity financing, subject to specified conditions.

Read more

Palo Alto, Calif. – Cooley advised Versartis on its $144.9 million initial public offering. Versartis, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders, now trades on the Nasdaq Global Stock Market under the symbol "VSAR."

Year-to-date in 2014, Cooley has advised on 38 completed public offerings, including 17 completed IPOs.

San Francisco – Cooley advised Adamas Pharmaceuticals on its initial public offering. Adamas, a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system, now trades on the Nasdaq Global Stock Market under the symbol "ADMS."

Thus far in 2014, Cooley has advised on 43 completed public offerings, including 22 completed IPOs.

Cooley advised Atara Biotherapeutics on its $63 million initial public offering, $74 million follow-on offering and $207 million follow-on offering.

Atara is a clinical stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company now trades on the Nasdaq Global Market under the symbol "ATRA."